title: Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus.
abstract: OBJECTIVE
  To determine the prevalence of abnormalities in myocardial perfusion or function in children with systemic lupus erythematosus (SLE), and describe potential factors that may predict their development.
  
  
  METHODS
  Patients (n = 40; 30 female) were enrolled through the Lupus Clinic at The Hospital for Sick Children between 1990 and 1992. Resting and exercise thallium myocardial perfusion scans, radionuclide angiography with multiple gated acquisition (MUGA), and resting M-mode and two-dimensional echocardiography were performed.
  
  
  RESULTS
  All patients were free of symptoms, and none had a history of ischemic heart disease. Their median age was 15.9 years (range 10.5 to 19.8 years) at enrollment. Abnormalities of coronary perfusion were found in 5 (16%) of 31 patients (95% confidence interval: 3%, 29%) and included a large fixed perfusion defect in 1; 5 of 27 MUGA scans showed marginally low left ventricular ejection fractions at rest, whereas all had normal exercise responses. In the group with abnormal thallium scans, three of five patients had antiphospholipid antibodies detected, and two of four had an abnormal plasma lipid profile. This group tended to have a shorter disease duration and had received a lower cumulative dose of corticosteroids; these differences were not statistically significant compared with the group with normal scans.
  
  
  CONCLUSIONS
  Asymptomatic abnormalities of myocardial perfusion occur in children with SLE and are more common than previously suspected. Patients with these abnormalities of myocardial perfusion may be predisposed to the previously recognized early-onset ischemic heart disease seen in adults with SLE.
authors.affiliation: Department of Pediatrics, Hospital for Sick Children, University of Toronto, Ontario, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Gazarian
authors.forename: B M
authors.initials: BM
authors.lastname: Feldman
authors.forename: L N
authors.initials: LN
authors.lastname: Benson
authors.forename: D L
authors.initials: DL
authors.lastname: Gilday
authors.forename: R M
authors.initials: RM
authors.lastname: Laxer
authors.forename: E D
authors.initials: ED
authors.lastname: Silverman
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017152:Antibodies, Antiphospholipid / Q000097:blood; D002648:Child; D004452:Echocardiography; D005080:Exercise Test; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006321:Heart / Q000000981:diagnostic imaging*; D006334:Heart Function Tests; D006801:Humans; D008055:Lipids / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000209:etiology*; D011875:Radionuclide Angiography; D013256:Steroids; D015899:Tomography, Emission-Computed, Single-Photon; D016276:Ventricular Function
chemical_list: D000893:Anti-Inflammatory Agents; D017152:Antibodies, Antiphospholipid; D005938:Glucocorticoids; D008055:Lipids; D013256:Steroids